Home Cart Sign in  
Chemical Structure| 1350653-20-1 Chemical Structure| 1350653-20-1

Structure of Vericiguat
CAS No.: 1350653-20-1

Chemical Structure| 1350653-20-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Vericiguat targets soluble guanylate cyclase (sGC) and is used for treating heart failure.

Synonyms: BAY1021189; Verquvo

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Vericiguat

CAS No. :1350653-20-1
Formula : C19H16F2N8O2
M.W : 426.38
SMILES Code : O=C(OC)NC1=C(N)N=C(C2=NN(CC3=CC=CC=C3F)C4=NC=C(F)C=C42)N=C1N
Synonyms :
BAY1021189; Verquvo
MDL No. :MFCD28502029
InChI Key :QZFHIXARHDBPBY-UHFFFAOYSA-N
Pubchem ID :54674461

Safety of Vericiguat

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Related Pathways of Vericiguat

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Bone marrow-derived monocyte-macrophage lineage (BMMs) 0-8 µM 24 hours To evaluate the cytotoxicity of Vericiguat on BMMs, results showed no cytotoxicity within 0-8 μM Mediators Inflamm. 2022 Jun 16;2022:1625290
Human aortic vascular smooth muscle cells (HVSMCs) 1 µM 24 hours To test whether vericiguat reverses HG-mediated decreased sGC activity. Results showed that cGMP production and PKG activity were significantly impaired in HG cells without vericiguat but were comparable to NG when treated with vericiguat. Sci Rep. 2025 Feb 10;15(1):4939
Bone marrow-derived monocyte-macrophage lineage (BMMs) 8 µM 6 days To evaluate the effect of Vericiguat on osteoclast differentiation, results showed 8 μM concentration inhibited osteoclast differentiation Mediators Inflamm. 2022 Jun 16;2022:1625290
Bone marrow-derived monocyte-macrophage lineage (BMMs) 500 nM 6 days To evaluate the effect of Vericiguat on osteoclast differentiation, results showed 500 nM concentration promoted osteoclast differentiation Mediators Inflamm. 2022 Jun 16;2022:1625290

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague Dawley rats Doxorubicin-induced cardiomyopathy model Intragastric administration 1 mg/kg/day Once daily for 8 weeks Vericiguat effectively reversed DOX-induced cardiac remodelling and improved systolic function. Mechanistically, Vericiguat attenuated the inhibitory effects of DOX on the myocardial cGMP-PKG axis and nuclear factor erythroid 2-related factor 2 (Nrf2) protein, thereby alleviating oxidative stress and apoptosis. ESC Heart Fail. 2025 Jun;12(3):1807-1817
Human Heart failure patients Oral 10 mg once daily Once daily for 10.8 months To evaluate the effect of Vericiguat in reducing the risk of cardiovascular death or heart failure hospitalization when added to standard therapy. Results showed a significant 10% reduction in the primary composite endpoint (cardiovascular death or first heart failure hospitalization). ESC Heart Fail. 2024 Apr;11(2):628-636
Mice Isolated mouse aortic rings Organ chamber bath 105.5 μM 24 hours To evaluate the effect of vericiguat on vascular relaxation in HG conditions. Results showed that ACh-mediated relaxation was impaired in HG but restored and even enhanced with vericiguat treatment. Sci Rep. 2025 Feb 10;15(1):4939
Rats Heart failure model Oral 3 mg/kg Once daily for 4 weeks To evaluate the therapeutic effect of Vericiguat on heart failure, results showed significant improvement in cardiac function PLoS One. 2023 Dec 22;18(12):e0295566
C57BL/6 mice Ovariectomy (OVX)-induced bone loss model Injection Low-dose group: 5 μg/kg/day; High-dose group: 10 μg/kg/day Once daily, duration not specified To evaluate the therapeutic effects of Vericiguat on OVX-induced bone loss, results showed high-dose Vericiguat (10 μg/kg/day) significantly improved bone loss Mediators Inflamm. 2022 Jun 16;2022:1625290
Human Patients with heart failure Oral Target dose of 10 mg Once daily, during the treatment period To evaluate the effect of vericiguat on the primary composite endpoint of cardiovascular death or first hospitalization for HF in patients with heart failure. Results showed that vericiguat significantly reduced the risk of the primary composite endpoint in the NT-proBNP Q1-Q3 group (HR 0.78; 95% CI 0.69–0.88, P<0.001), but no significant difference was observed in the Q4 group (HR 1.15; 95% CI 0.99–1.34, P=0.070). ESC Heart Fail. 2022 Dec;9(6):3791-3803

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06321094 Acute Coronary Syndrome|Heart ... More >>Failure With Reduced Ejection Fraction Less << PHASE4 RECRUITING 2025-12-01 the First Affiliated Hospital ... More >>of Nanjing Medical University, Nanjing, Jiangsu, China Less <<
NCT06415227 Vasospastic Angina PHASE2 NOT_YET_RECRUITING 2026-06-01 -
NCT06812546 Heart Failure|Acute Myocardial... More >> Infarction (AMI)|Acute Heart Failure (AHF) Less << PHASE4 NOT_YET_RECRUITING 2026-12-30 The First Affiliated Hospital ... More >>of Chongqing Medical University, Chongqing, 400000, China Less <<
NCT06601465 Heart Failure|Cognitive Impair... More >>ment Less << PHASE2 NOT_YET_RECRUITING 2025-05-27 University of Calgary, Calgary... More >>, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|University of Ottawa, Ottawa, Ontario, Canada|McGill University Health Center, Montreal, Quebec, Canada Less <<
NCT05704478 Heart Failure PHASE4 NOT_YET_RECRUITING 2027-03-31 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.35mL

0.47mL

0.23mL

11.73mL

2.35mL

1.17mL

23.45mL

4.69mL

2.35mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories